Resverlogix is Presenting at IAS HDL Workshop

Calgary, Canada (ots/PRNewswire) -

- Novel ApoA-I/HDL Raising Drug, RVX-208, to be Featured in Oral
Presentation

Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce
that tommorrow it is making an oral presentation highlighting key
scientific data of its lead clinical molecule, RVX-208, at the
International Atherosclerosis Society (IAS) Workshop on HDL. The
presentation titled "A novel drug that raises apolipoprotein A-I and
HDL in vitro and in vivo" will be presented by Dr. Norman Wong,
Resverlogix Co-Founder and Chairman of the Scientific Advisory Board
on October 12th at the Petros M. Nomikos Conference Center in
Santorini, Greece.

"This meeting of the IAS attracts internationally elite scientists
in cardiovascular medicine. This venue is ideal for announcing the
favorable and novel features of RVX-208, scheduled for clinical
trials later this year," stated Dr. Jan Johansson, MD, Ph.D., Senior
Vice President, Clinical Affairs of Resverlogix. Dr. Johansson added,
"RVX-208 is a small molecule for oral administration that has shown
to have unprecedented effects in raising ApoA-I and functional HDL.
There is an ever-increasing body of evidence from predictive animal
models that indicates RVX-208's potential for preventing and
regressing atherosclerosis. We are very happy to participate in this
important conference."

Mr. Donald McCaffrey, President and CEO of Resverlogix said,
"These highly regarded researchers who will be participating at the
event clearly understand that there is a large unmet medical need in
cardiovascular disease (CVD). There is a lot of excitement among
these key opinion leaders that Resverlogix's novel small molecule
drug could address many of the shortcomings of current CVD drugs."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

Website: http://www.resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp.,
Phone:+1-403-254-9252, Fax:+1-403-256-8495, Email:
Sarah@resverlogix.com